Evidence map›Paper›PMID 34419152›Full record

ReviewBiomarker research2021

Emerging treatment modalities for systemic therapy in hepatocellular carcinoma.

Xin Qing, Wenjing Xu, Jingjing Zong, Xuanlong Du, Hao Peng, Yewei Zhang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Relationships Among Serological Indicators andCombinatorial chemistry & high throughput screening · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xin Qing *Department of General Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
Wenjing Xu *Department of General Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
Jingjing ZongDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
Xuanlong DuDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
Hao PengDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
Yewei ZhangDepartment of General Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China. zhangyewei@seu.edu.cn.
Zhongda Hospital Southeast University · CN

Funding

Key Medical Talents Foundation of Jiangsu Province 2016KJQWZDRC-03National Natural Science Foundation of China 62041101National Natural Science Foundation of China 81872255
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) has long been a major global clinical problem as one of the most common malignant tumours with a high rate of recurrence and mortality. Although potentially curative therapies are available for the early and intermediate stages, the treatment of patients with advanced HCC remains to be resolved. Fortunately, the past few years have shown the emergence of successful systemic therapies to treat HCC. At the molecular level, HCC is a heterogeneous disease, and current research on the molecular characteristics of HCC has revealed numerous therapeutic targets. Targeted agents based on signalling molecules have been successfully supported in clinical trials, and molecular targeted therapy has already become a milestone for disease management in patients with HCC. Immunotherapy, a viable approach for the treatment of HCC, recognizes the antigens expressed by the tumour and treats the tumour using the immune system of the host, making it both selective and specific. In addition, the pipeline for HCC is evolving towards combination therapies with promising clinical outcomes. More drugs designed to focus on specific pathways and immune checkpoints are being developed in the clinic. It has been demonstrated that some drugs can improve the prognosis of patients with HCC in first- or second-line settings, and these drugs have been approved by the Food and Drug Administration or are nearing approval. This review describes targeting pathways and systemic treatment strategies in HCC and summarizes effective targeted and immune-based drugs for patients with HCC and the problems encountered.

Indexed as

Hepatocellular carcinomaImmune checkpoint inhibitorsImmunotherapySignalling pathwayTargeted therapyTyrosine kinase inhibitors

Identifiers

PMID34419152
PMCPMC8380325
OpenAlexW3193373750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.